Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2930 and TQB2102 in HER2-Expressing Advanced Solid Tumors
NCT07512583Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930 injection + oxaliplatin + capecitabine + bevacizumab, TQB2102 in solid tumor (advanced stage), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
TQB2930 injection + oxaliplatin + capecitabine + bevacizumabTQB2102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07512583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512583.